On September 7, 2022 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, reported that company management will participate in two upcoming investor conferences in September (Press release, Adicet Bio, SEP 7, 2022, View Source [SID1234619191]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the events are as follows:
H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022, New York, New York
An on-demand presentation given by Chen Schor, President & CEO will be available beginning Monday, September 12, 2022 at 7:00 A.M. ET
Jefferies Cell and Genetic Medicine Summit, September 29-30, 2022, New York, New York
Chen Schor, President & CEO, will present a corporate overview on Friday, September 30, 2022, at 8:00 A.M. ET.
The live audio webcast of the presentations can be accessed on the Investors section of Adicet Bio’s website at View Source An archived replay will be available for 30 days following the presentation.